Comparison of Transcatheter Arterial Microembolization and Corticosteroid Injection and for Treatment of Frozen Shoulder
RecruitingNot applicableNCT07696923
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Objectives： This study aims to compare the efficacy of transcatheter arterial microembolization (TAME) and corticosteroid injection for treatment of frozen shoulder. Background： Frozen shoulder (adhesive capsulitis) is a common condition that leads to significant functional impairment and reduced quality of life. Current treatment options are diverse, including pharmacological therapy, physical rehabilitation, corticosteroid injection, hydrodilatation, and the more recently developed transcatheter arterial microembolization (TAME). Corticosteroid injection, due to its anti-inflammatory effects, has been shown in numerous clinical studies to provide short-term pain relief and improved range of motion; however, its benefits are often limited to several weeks or months, and some patients continue to experience persistent symptoms. In contrast, TAME has emerged as a novel treatment for musculoskeletal disorders by targeting abnormal neovascularization and inflammatory processes in the affected tissues, there by achieving pain reduction. Multiple studies from both international and domestic medical centers have demonstrated its safety and efficacy, though most reports focus on case reports or case series observational outcomes. To date, there is a lack of clinical trials directly comparing the therapeutic outcomes of TAME versus corticosteroid injection in patients with frozen shoulder. Study Design： This study is a single-center, prospective, randomized controlled trial (RCT). Methods： A total of 94 patients diagnosed with frozen shoulder in the freeing stage will be recruited from the Department of Physical Medicine and Rehabilitation at Shin Kong Hospital. Eligible patients will be randomly assigned to either the transcatheter arterial microembolization (TAME) group and the corticosteroid injection (CS) group. The arterial microvascular embolization group will receive one treatment, while the corticosteroid injection group will receive two corticosteroid injections in…
Study details
- Official title
- Comparison of Transcatheter Arterial Microembolization and Corticosteroid Injection and for Treatment of Frozen Shoulder
- Conditions
- Frozen Shoulder
- Chronic Pain
- Adhesive Capsulitis
- Transcatheter Arterial Microembolization
- Corticosteroid Injection
- Interventions
- Other: TAME group
- Other: CS injection group
- Sponsor
- Shin Kong Wu Ho-Su Memorial Hospital
- Start date
- 2026-08-01
- Primary completion
- 2028-07-31
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- Taiwan
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * 1). age between 18 to 80 years old; * 2). shoulder pain for ≥ 1 month; * 3). \> 30% loss of passive range of motion (ROM) of the affected shoulder in external rotation and/or abduction, comparing with the sound side; * 4). pain VAS on maximal passive external rotation or abduction \> 4; * 5). showing willing to receive TAME, or shoulder joint injection, and attend regular physical therapy programs for 4 weeks. * 6). an empty or soft end feel during passive external rotation or abduction and/or night or rest pain. Exclusion Criteria: * 1). severe systemic disorders including cancer, stroke, or cardiopulmonary diseases; * 2). uncontrolled DM; * 3). rotator cuff tear or calcification of the affected shoulder; * 4). fracture, dislocation, or arthritis of the shoulder due to rheumatic disorders; - 5). a history of allergy to local anesthetics, corticosteroids, imipenem/cilastatin sodium or contrast medium; * 6). pregnancy; * 7). corticosteroid joint or subdeltoid bursa injection of the affected shoulder during the preceding three months; * 8). receiving TAME of the affected shoulder during the preceding six months.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07696923